Form 8-K

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JbGuzFUj0XPMIFnH9D4VKpgPbUFjOPpEiYAPYpU7QYk0ax1QD5//upHrAFjilDOz hbSzrqMNk9DzcVAKUBLPgg== 0001193125-09-198566.txt : 20090928 0001193125-09-198566.hdr.sgml : 20090928 20090928070332 ACCESSION NUMBER: 0001193125-09-198566 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090928 ITEM INFORMATION: Other Events FILED AS OF DATE: 20090928 DATE AS OF CHANGE: 20090928 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYMOGENETICS INC CENTRAL INDEX KEY: 0001129425 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911144498 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33489 FILM NUMBER: 091089116 BUSINESS ADDRESS: STREET 1: 1201 EASTLAKE AVENUE E CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-442-6600 MAIL ADDRESS: STREET 1: 1201 EASTLAKE AVENUE E CITY: SEATTLE STATE: WA ZIP: 98102 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

September 28, 2009

Date of Report (Date of earliest event reported)

ZYMOGENETICS, INC.

(Exact name of registrant as specified in its charter)

Washington

000-33489

91-1144498

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

1201 Eastlake Avenue East

Seattle, Washington

98102-3702

(Address of principal executive offices)

(Zip Code)

(206) 442-6600

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events.

ZymoGenetics’ licensee, Merck Serono SA, recently decided to voluntarily discontinue the ongoing studies in multiple sclerosis (MS) for the investigational drug atacicept. This decision was taken based upon a recommendation from an Independent Data Monitoring Committee (the Committee), who determined that the risk/benefit relationship did not justify the continuation of these studies. In one of the studies, the Committee observed an increase in MS disease activity (mean number of relapses and MRI lesions) in the atacicept treatment arms compared to the placebo arm. Two ongoing studies of atacicept, one in rheumatoid arthritis and one in systemic lupus erythematosus, are continuing, as no comparable issues have been identified in these studies.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ZYMOGENETICS, INC.

Date: September 28, 2009	By:	/s/ JAMES A. JOHNSON
		James A. Johnson Executive Vice President, Chief Financial Officer, Secretary and Treasurer

-----END PRIVACY-ENHANCED MESSAGE-----